| Identification | Back Directory | [Name]
Odapipam | [CAS]
131796-63-9 | [Synonyms]
Nnc 756
Odapipam
Nnc 01-0756
Odapipam [inn]
(S)-8-Chloro-5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-ol
(S)-8-Chloro-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol
1H-3-Benzazepin-7-ol, 8-chloro-5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-, (5S)- | [Molecular Formula]
C19H20ClNO2 | [MDL Number]
MFCD00868632 | [MOL File]
131796-63-9.mol | [Molecular Weight]
329.82 |
| Chemical Properties | Back Directory | [Boiling point ]
460.4±45.0 °C(Predicted) | [density ]
1.269 | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
8.84±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Odapipam (NNC 756) is a selective, high affinity and benzazepine dopamine D1 receptor antagonist with a Kd of 0.18 nM. Odapipam is also a superior positron emission tomography (PET) radiotracer[1][2]. | [in vivo]
The metabolism of Odapipam has been studied with phenobarbital-induced rat liver microsomes. During the incubation of Odapipam, five different metabolites are formed. The electron-ionization (EI+) mass spectra of the metabolites indicated the formation of N-desmethyl-Odapipam, 1-hydroxy-Odapipam, the two isomers of 3′-hydroxy-Odapipam and a metabolite which is dehydrogenated in the dihydrobenzofuran moiety[3]. | [References]
[1] Abi-Dargham A, et al. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse. 1999 May;32(2):93-109. DOI:10.1002/(SICI)1098-2396(199905)32:23.0.CO;2-C
[2] Nielsen EB, et al. Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Aug 14;219(1):35-44. DOI:10.1016/0014-2999(92)90577-q
[3] J. VANGGAARD ANDERSEN, et al. Normal-phase liquid chromatography-particle-beam mass spectrometry in drug metabolism studies of the dopamine receptor antagonist Odapipam and the muscarine M1 receptor agonist Xanomeline. Xenobiotica. 1997, 27: 901-912. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
| Company Name: |
Axon Medchem BV
|
| Tel: |
+31-50-3118007 |
| Website: |
www.axonmedchem.com |
|